Michael E. Tarnoff - 03 Jun 2026 Form 4 Insider Report for AVITA Medical, Inc. (RCEL)

Reporting relationship: Director
Issuer ticker: RCEL
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jun 2026, 19:09:40 UTC
Prior SEC filing: 06 Aug 2025
Next SEC filing: 22 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Nicole Kelsey, by power of attorney

Key filing fact

Michael E. Tarnoff filed Form 4 for AVITA Medical, Inc. (RCEL) on 04 Jun 2026.

Key facts

This page summarizes Michael E. Tarnoff's Form 4 filing for AVITA Medical, Inc. (RCEL).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Jun 2026, 19:09.

Change

Previous filing in this sequence was filed on 06 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001603289 Primary reporting owner

Tarnoff Michael E

Relationship: Director
Address: C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA
Signature: /s/ Nicole Kelsey, by power of attorney
Signature date: 04 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCEL transaction

Common Stock

Award

Transaction value
Shares: +26,250
Change %
Price
Shares after: 26,250
Date: 06 Aug 2025
Ownership: Direct
Footnotes: F1, F2

RCEL transaction

Common Stock

Award

Transaction value
Shares: +22,214
Change %: +85%
Price
Shares after: 48,464
Date: 20 Jan 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCEL transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +19,063
Change %
Price: $0.000000^*
Shares after: 19,063
Date: 06 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,063
Exercise price: $5.36
Footnotes: F4, F5

RCEL transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +16,133
Change %
Price: $0.000000^*
Shares after: 16,133
Date: 20 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,133
Exercise price: $3.77
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments on the date 12 months following the grant date of August 6, 2025. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

Footnote F2

Includes unvested RSUs

Footnote F3

Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

Footnote F4

On August 6, 2025, the Board of Directors approved a grant of 19,063 options to acquire 19,063 shares of Common Stock of the Company to Dr. Tarnoff as a new non-executive director, with an effective grant date of August 6, 2025 and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on August 6, 2025 of $5.36. The grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

Footnote F5

These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date.

Footnote F6

On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.